Volume 10, Issue 4 (winter 2014)                   Sci J Iran Blood Transfus Organ 2014, 10(4): 326-334 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Anedi M, Rahgozar S, Moafi A, Ghaedi K, Moshtaghian S, Entezar-e-Ghaem M et al . Evaluation of the expression profile of MDR1 geneand assessment of its prognostic value in childhood ALL. Sci J Iran Blood Transfus Organ 2014; 10 (4) :326-334
URL: http://bloodjournal.ir/article-1-824-en.html
Evaluation of the expression profile of MDR1 geneand assessment of its prognostic value in childhood ALL
M. Anedi , S. Rahgozar * , A.R. Moafi , K. Ghaedi , S.J. Moshtaghian , M.S. Entezar-e-Ghaem , F. Montazeri
Keywords: Key words: Lymphoblastic Leukemia٬ Acute, Multidrug Resistance, Minimal Residual Disease, Gene Expression Profiles
Full-Text [PDF 498 kb]   (2900 Downloads)     |   Abstract (HTML)  (12520 Views)
Full-Text:   (4020 Views)
References:
 
  1. Beishuizen A. Immunogenetic studies in childhood acute lymphoblastic leukemia: analysis at diagnosis and relapse [dissertation]. Rotterdam: Afdeling tmmunologie, Erasmus Universiteit; 1994. p. 249.
  2. Lugthart S, Cheok MH, den Boer ML, Yang W, Holleman A, Cheng C, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005; 7(4): 375-86.
  3. Szczepanek   J,  Styczyński   J,  Haus    O,  Tretyn   A,
Wysocki M. Relapse of acute lymphoblastic leukemia in children in the  context of microarray analyses. Arch
Immunol Ther Exp (Warsz) 2011; 59(1): 61-8.
  1. Gaynon PS. Childhood Acute Lymphoblastic Leukemia and Relapse. Us S Pecial Populations Pediatrics Review 2006; 1-7.
  2. Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2006; 108(2):
711-7.
  1. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14(3): 467-73.
  2. Swerts  K,  De  Moerloose  B,   Dhooge  C, Laureys G,
Benoit Y, Philippé J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 2006; 42(3): 295-309.
  1. Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 2007; 453(5): 621-41.
  2. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8(5): 411-24.
  3. Ambudlkar  SV ,   Kimchi - Sarfaty   C ,   Sauna    ZE.,
Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22(47): 7468-85.
  1. Tsuruo T. Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med 2003; 42(3): 237-43.
  2. Lage H. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by RNA interference. International Congress Series 2005; 1277: 144-53.
  3. Abedi M, Rahgozar S. Molecular mechanisms of drug resistance in acute lymphoblastic leukemia. The 6th Annual Congress of Iranian Blood and pediatric cancer Society; 2011; Ahwaz. p. 74.
  4. Abedi M, Rahgozar S. Iron deprivation effects on leukemic cells. Iranian Journal of Pediatric Hematology & Oncology 2012; 2(2(Supplement 1)): 57.
  5. Fang D, Bao Y, Li X, Liu F, Cai K, Gao J, et al. Effects of iron deprivation on multidrug resistance of leukemic K562 cells. Chemotherapy 2010; 56(1): 9-16.
  6. Biondi A, Baruchel A, Hunger S, Masera G, Schmiegelow K, Schrappe M, et al. The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia 2009; 23(12): 2318-24.
  7. Cortez MA, Scrideli CA, Yunes JA, Valera ET, Toledo SR, Pavoni-Ferreira PC, et al. mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. Pediatr Blood Cancer 2009; 53(6): 996-1004.
  8. Aouali N, Eddabra L, Macadré J, Morjani H. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 2005; 56(1): 61-70.
  9. Mruk  DD,  Su  L,  Cheng  CY.  Emerging role for drug transporters at  the   blood - testis  barrier.  Trends
Pharmacol Sci 2011; 32(2): 99-106.
  1. Marques DS, Sandrini JZ, Boyle RT, Marins LF, Trindade GS. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leuk Res 2010; 34(6): 757-62.
  2. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79(2): 473-6.
  3. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology 2009; 14(4): 204-12.
  4. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008; 1(2): 93-105.
  5. El-Sharnouby JA, Abou El-Enein AM, El Ghannam DM, El-Shanshory MR, Hagag AA, Yahia S, et al. Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia. J Oncol Pharm Pract 2010; 16(3): 179-88.
  6. Huh HJ, Park CJ, Jang S, Seo EJ, Chi HS, Lee JH, et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006; 21(2): 253-8.
  7. Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T, et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes  and  clinical   outcome     in     childhood    acute

lymphoblastic leukemia. Int J Hematol 2007; 86(2): 166-73.
  1. Valera ET, Scrideli CA, Queiroz RG, Mori BM, Tone LG. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 2004; 122(4): 166-71.
  2. Kanerva J, Tiirikainen MI, Mäkipernaa A, Riikonen P, Möttönen M, Salmi TT, et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up. Pediatr Hematol Oncol 2001; 18(1): 27-36.
  3. Olson DP, Taylor BJ, La M, Sather H, Reaman GH, Ivy SP. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 2005; 46(5): 681-91.
  4. Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002; 100(3): 974-81.
  5. Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, et al. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2007; 133(11): 875-93.
  6. Gurbuxani S, Sazawal S, Arya LS, Raina V, Marie JP, Bhargava M. MDR1 mRNA expression in young patients with acute lymphoblastic leukaemia. Br J Haematol 2000; 109(4): 897-9.
 
 
Original Article
 
 
 
 
Sci J Iran Blood Transfus Organ 2014; 10(4): 326-334
 

 
 
Evaluation of the expression profile of MDR1 gene
and assessment of its prognostic value in childhood ALL
 
Abedi M.1, Rahgozar S.1, Moafi A.R.2, Ghaedi K.1, Moshtaghian S.J.1,
 Entezar-e-Ghaem M.S.1, Montazeri F.1
 
 
1Faculty of Science, University of Isfahan, Isfahan, Iran
2Faculty of Medicine,  Isfahan University of  Medical Sciences, Isfahan, Iran
 
 
 
Abstract
Background and Objectives
Acute lymphoblastic leukemia (ALL) is the most common cancer among children. Multi drug resistance (MDR) is the major cause of treatment failure and relapse in ALL. ABC transporters mainly contribute to this disorder and MDR1 gene is the most popular member of this family. The aim of this study is to evaluate the gene expression profile of MDR1 at mRNA level and its prognostic value in ALL.
 
Materials and Methods
Bone marrow and peripheral blood samples were obtained from 28 newly diagnosed ALL patients and 15 controls. MDR1 gene expression profile was evaluated by using real time PCR. The minimal residual disease (1-year MRD) was considered as the factor of response to therapy. Data were analyzed by using SPSS 20 and Graph Pad Prism 5 softwares.
 
Results
MDR1 gene expression level in patients with MRD+ was significantly higher than MRD- patients (2.29 ± 1.22 vs 0.79 ± 0.21)(mean ± SEM, p= 0.049). Most of the patients with over expression of MDR1 gene were MRD+ (66.6% vs 33.3)(mean ± SEM, p= 0.048).
 
Conclusions 
MDR1 gene expression profile is suggested to be an unfavorable prognostic factor in ALL. The evaluation of the mRNA expression profile of MDR1 in new case patients facilitates identification of the high risk patients and helps modifying the protocols applied for ALL treatment in order to improve the therapeutic outcome.
 
Key words: Lymphoblastic Leukemia٬ Acute, Multidrug Resistance, Minimal Residual Disease, Gene Expression Profiles
 
 
 
 
 
Received:   8 Dec  2012
Accepted: 12 May 2013
 
 
 

Correspondence: Rahgozar S., PhD of Immuno-Hematology. Assistant Professor of Faculty of Science, University of Isfahan, Hezarjerib St.
Postal Code: 81746-73441, Isfahan, Iran. Tel: (+98311) 7932365; Fax: (+98311)7932456
E-mail:
 rahgozar@sci.ui.ac.ir
Type of Study: Research | Subject: Hematology and Oncology
Published: 2013/12/18
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb